As result, we identified five target genes of metformin (RPS6KA5, RORA, SH3BP5, NUPR1, and CD40LG), which were significantly correlated with favorable prognosis and immune infiltration in lung cancer patients. This evidence concerns the gene RORA and lung cancer.